Fluconazole (all routes except local only) - Cumulative dose > 150 mg updated on 01-29-2025

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
All congenital malformations (majors, minors, majors and minors, or unspecified)1.20 [0.99, 1.46]0%2 studies44,7503,670not evaluable ROB-
Limb defects1.18 [0.80, 1.75]0%2 studies12,4413,670not evaluable ROB-
Major congenital malformations1.20 [0.99, 1.46]0%2 studies44,7503,670not evaluable ROB-
Cardiac septal defects1.81 [1.04, 3.15]-1 study3,282400not evaluable ROB3.02 [1.25; .]
Polydactyly2.71 [1.01, 7.27]-1 study2,252not evaluable ROB4.86 [1.11; .]
13 non statistically significant endpoints reported in only one study

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
1 non statistically significant endpoints reported in only one study

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions2.42 [1.28, 4.56]73%3 studies30,0701,238not evaluable ROB4.27 [1.88; .]
Late intrauterine deaths (> 22 weeks) / Stillbirths1.31 [0.32, 5.34]85%3 studies1,1955,153not evaluable ROB-